# IAMA Therapeutics S.r.l.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iama-therapeutics-s-r-l

- Industry: Pharmaceuticals
- Headquarters: Genoa, Italy
- Website: www.iamatherapeutics.com
- Total disclosed funding: $9M
- Latest round: Series A (Dec 1, 2021)
- Investors on record: 2

## About

Based in Genoa, Italy, and founded in 2021 by Laura Cancedda, and Marco De Vivo, IAMA Therapeutics S.r.l. is a neuroscience drug discovery company that operates as a provider of therapeutic solutions that primarily helps children suffering from brain disorders. In December 2021, IAMA Therapeutics S.r.l. raised EUR 8 million in Series A funding from new investors CDP Venture Capital and Claris Ventures. As of May 2022, the company is being led by Andrea Patricelli Malizia as its CEO.

The company has created a platform for discovering and developing new small compounds that selectively inhibit the sodium-potassium chloride cotransporter (NKCC1) and other therapeutic targets in the central nervous system. The firm is involved in the research of NKCC1 inhibitors in treating idiopathic and secondary forms of autism (autism spectrum disorder -ASD-), refractory epilepsy, and other neurological disorders.

## Funding rounds

- Series A, Dec 1, 2021, $9M — CDP Venture Capital, Claris Ventures

## Investors

- CDP Venture Capital (https://capitalatlas.ai/funds/cdp-venture-capital) — Series A
- Claris Ventures (https://capitalatlas.ai/funds/claris-ventures) — Series A